

Replication Pricing of xVA and the Asset-Liability Symmetry

Lixin Wu

Department of Mathematics
The Hong Kong University of Science and Technology

Joint work with Dawei Zhang, HKUST

Outline of the presentation

- 1 xVA — the new paradigm of derivatives pricing
- 2 Risk-neutral valuation and the bilateral replication strategy
- 3 The rise of other xVA
- 4 Market funding liquidity risk premium and asset-liability symmetry

Table of Contents

- 1 xVA — the new paradigm of derivatives pricing
- 2 Risk-neutral valuation and the bilateral replication strategy
- 3 The rise of other xVA
- 4 Market funding liquidity risk premium and asset-liability symmetry

Risk-neutral pricing

$$V_e(0) = E_0^Q[e^{-\int_0^T r_s ds} V_T],$$

where

- r_t — the risk-free rate,
- \mathbb{Q} — A risk-neutral measure.

When the counterparty default risk is taken into account, the value becomes

$$V(0) = V_e(0) + CVA,$$

where CVA, for *credit valuation adjustment*, is defined by

$$CVA = -\text{Prob}(\tau \leq T) \times L \times \underbrace{V_e(0)}_{\text{Loss rate}}.$$

- FASB 157 and IAS 39 were introduced in 2004 to price in counterparty risks.
- Banks started to make CVA on a monthly basis.

When the funding risk is further taken into account, then

$$V(0) = V_e(0) + CVA + DVA + FVA,$$

where

DVA — counterparty's CVA and

FVA — is for **funding valuation adjustment**, with a popular definition

$$FVA = -E_0^Q \left[\int_0^{\tau \wedge T} x e^{-\int_0^u r_s ds} V_e(u) du \right],$$

with x is the investor's funding spread. This formula is

- originated from hedging OTC swap with a fully collateralized swap.
- CVA and FVA formula have been generalized to a portfolio.

Definition of FVA

FVA — the **funding cost/benefit** resulted from borrowing or lending the shortfall/excess of cash arising from day-to-day derivatives business operations (for example, **hedging and collateral posting/ receiving**).

Risk Dynamics Blog, 2012

- A trade is **made** at the price $V_e(0)$.
- Yet the the trade can be **booked** using the economic value:

$$V(0) = V_e(0) + CVA + DVA + FVA.$$

- Making BCVA (i.e., CVA+DVA) is now a standard market practice.
- Some banks have made a triad of valuation adjustments (**CVA**, **DVA** and **FVA**), as early as 2012.
 - Royal Bank of Scotland reported FVA of £475 million (4Q 2012).
 - JP Morgan books \$1.5bn FVA loss in the 4Q 2013 (Reuter).
 - Nomura books ¥10 billion FVA loss in the 4Q 2103 (Risk.net).
 - Citi takes \$474 million FVA charge in 3Q 2014 (Risk.net).
 - Morgan Stanley takes \$468m FVA loss in the 4Q 2014 (Risk.net).

The xVA

xVA means a list of valuation adjustments:

- Credit valuation adjustment (CVA) (settled).
- Funding valuation adjustment (FVA):
 - Funding cost adjustment (FCA).
 - Collateral valuation adjustment (COLVA).
 - Capital valuation adjustment (KVA).
 - Margin valuation adjustment (MVA).
 - Liquidity valuation adjustment (LVA).
- Taxation valuation adjustment (TVA).
- etc.

Discussions are undergoing on setting up the “xVA” desks (Carver, 2013).

Controversies surrounding the xVA

- Pricing in funding cost or booking FVA for P&L accounting cause asset-liability asymmetry.
- Hull and White (2012-) reject FVA.
- Over two-thirds say the current FVA approach is wrong - Risk.net poll (March 2015).
- The prevalent FVA models overstate costs (Albanese & Andersen, 2015).
- “There’s no convergence on how FVAs should be calculated, and everybody is doing it differently, because at the moment there are no right or wrong answers. Quite frankly, it’s a bit of a mess.”
— An auditor (Cameron, 2013)

In literature xVA is often treated as part of “value to me”.

- The master formula based on the risk-neutral valuation principle (Brigo *et al.*, 2007-).
- Extending the Black-Scholes model for FVA (Piterbarg, 2010; Lou, 2015).
- BSDE approach (Crepey, 2011-12, Bichuch *et al.*, 2015).
- Replication pricing of CVA and FVA (Burgard and Kjaer, 2011-);
- Enhanced replication pricing (Wu, 2013-).
- Replication pricing to include KVA and MVA (Green & Kenyon, 2014-15).

The main questions

For a derivative trade, bilateral or CCP,

- what should be the fair price?
- how should the trade be booked?

- The fair price is $(NDV + BCVA) + FVA_{mkt}$.
- This price is for both trading and booking.

Asset-liability symmetry is retained in both trading and booking, and it is in line with the emerging market consensus!

Table of Contents

- 1 xVA — the new paradigm of derivatives pricing
- 2 Risk-neutral valuation and the bilateral replication strategy**
- 3 The rise of other xVA
- 4 Market funding liquidity risk premium and asset-liability symmetry

Some notations

- Y_T — the contractual payoff of the derivative at maturity T
- τ_i — the default time of party i , $i = B$ and C
- $I_i(t)$ — ≥ 0 , the value of the initial margin (IM)
- $X_i(t)$ — ≥ 0 , the value of the variable margin (VM) or collaterals
- $K_i(t)$ — ≥ 0 , the value of the capital
- $V(t)$ — the value of the derivative fair to B , the bank, s.t.
 - $V(t) > 0$ — asset,
 - $V(t) < 0$ — liability

We will model the market by $(\Omega, \mathcal{G}, \mathcal{G}_t, \mathbb{P})$, where

- \mathbb{P} — the real-world measure,
- \mathcal{G}_t — $\mathcal{F}_t \vee \mathcal{H}_t$, where
 - \mathcal{F}_t : all market information except defaults, while
 - \mathcal{H}_t : default status, $\sigma(\{\tau_B \leq u\} \vee \{\tau_C \leq u\} : u \leq t)$

Minor assumptions:

- 1 the risk-free rate, CDS rates and recovery rates are constants;
- 2 there is no default by the current moment $t = 0$, i.e., $\tau > 0$.

The derivative payoff Y_T can be \mathcal{G}_T -adaptive (so there is no restriction on issuer of the underlying).

Features of the pricing problem

- An equity derivative.
- Counterparties default risks.
- Funding costs/risks
 - repo spreads (haircut for capital or fee for short selling);
 - borrowing spreads for IM, VM and capital;
 - rehypothecation benefit.

Two-step pricing strategy

- 1 Ignore funding costs, and
 - let the party of liability replicate the derivatives payoff (using e.g. repos);
 - let the party of exposure replicate the LGD (using CDS);
 - set the derivatives value as the difference of the replication costs.
- 2 Take into account funding costs, and calculate the xVA for replication, margin/collateral posting and capital.

The primary securities are saving account, share and CDS, which have the following \mathbb{P} dynamics:

$$dB_t = r_t B_t dt,$$

$$dS_t = S_t \left[\mu_t dt + \sigma_t dW_t^{(P)} \right],$$

$$dU_i(t) = r_t U_i(t) dt - s_i dt + L_i dJ_i^{(P)}, \quad i = B \text{ and } C,$$

At hedge revision, we will use par CDS, such that $U_i(t) = 0$.

The risk-neutral measure

The risk-neutral measure is defined by

$$\begin{aligned}\frac{dQ}{dP}\Big|_{\mathcal{F}_t} &= \frac{e^{-\int_0^t \gamma_S(u) dW_u^{(P)}}}{E_0^P \left[e^{-\int_0^t \gamma_S(u) dW_u^{(P)}} \right]} \frac{e^{\gamma_B J_B^{(P)}(t)}}{E_0^P \left[e^{\gamma_B J_B^{(P)}(t)} \right]} \frac{e^{\gamma_C J_C^{(P)}(t)}}{E_0^P \left[e^{\gamma_C J_C^{(P)}(t)} \right]} \\ &= e^{\int_0^t -\frac{1}{2}\gamma_S^2(u) du + \gamma_S(u) dW_u^{(P)} + \gamma_B J_B^{(P)}(t) + \lambda_B^{(P)} t(1 - e^{\gamma_B}) + \gamma_C J_C^{(P)}(t) + \lambda_C^{(P)} t(1 - e^{\gamma_C})},\end{aligned}$$

with

$$\begin{aligned}\gamma_S(t) &= \frac{\mu_t - r_t - \lambda_S + q_t}{\sigma_S}, \\ \gamma_B &= \ln \frac{S_B/L_B}{\lambda_B^{(P)}} \quad \text{and} \quad \gamma_C = \ln \frac{S_C/L_C}{\lambda_C^{(P)}}.\end{aligned}$$

Proposition

The risk-neutral valuation of the derivative to the counterparties is

$$V_f(0) = E_0^Q \left[e^{-\int_0^{\tau \wedge T} r_s ds} V(\tau \wedge T) \right] \quad \square \quad (1)$$

Corollary

When Y_T is \mathcal{F}_T -adaptive, the risk-neutral valuation of the derivative has the following decomposition:

$$V_f(0) = V_e(0) + CVA_B + CVA_C, \quad (2)$$

where

$$\begin{aligned} CVA_B &= E_0^Q[1_{\{\tau=\tau_B \leq T\}} e^{-\int_0^{\tau_B} r_s ds} (V(\tau_B) - V_e(\tau_B))], \\ CVA_C &= E_0^Q[1_{\{\tau=\tau_C \leq T\}} e^{-\int_0^{\tau_C} r_s ds} (V(\tau_C) - V_e(\tau_C))] \quad \square \end{aligned} \quad (3)$$

Note that

- $V_e(0) + CVA_C$ is the replication cost of B , and
- CVA_B is the replication cost of C .

Table of Contents

- 1 xVA — the new paradigm of derivatives pricing
- 2 Risk-neutral valuation and the bilateral replication strategy
- 3 The rise of other xVA**
- 4 Market funding liquidity risk premium and asset-liability symmetry

The rise of other xVA

Once B and C enter into a trade at time $t = 0$ for a value V_0 to B , the two parties start hedging, posting margins/collaterals and setting aside capital. The hedging portfolios of the two parties can be expressed as

$$\begin{aligned}\Pi_B(t) &= \delta_B Z_S(t) + \alpha_B U_C(t) + \beta_B(t), \\ \Pi_C(t) &= \delta_C Z_S(t) + \alpha_C U_B(t) + \beta_C(t),\end{aligned}\tag{4}$$

where δ_i is the number of repo contracts held by party i , which can be

$$\delta_B = -\frac{\partial V_e(t)}{\partial S}, \quad \delta_C = \frac{\partial V_e(t)}{\partial S},$$

and α_i is the numbers of CDS contract taken up by party i to hedge against LGD:

$$\alpha_B(t) = -\frac{V(\tau_C = t) - V_e(t)}{L_C}, \quad \alpha_C(t) = -\frac{V(\tau_B = t) - V_e(t)}{L_B},$$

The cash accounts

$\beta_i(t)$ is the total value of party i 's cash and funding transactions, such that

$$\beta_i(t) = \beta_{m,i}(t) + Z_i^{(I)}(t) + Z_i^{(X)}(t) + Z_i^{(K)}(t), \quad i = B \text{ and } C.$$

Here,

- $\beta_{m,i}(t)$ — saving account used for unsecured borrowing and for depositing the P&L from hedging and funding,
- $Z_i^{(I)}(t)$ — = 0, zero-net funding transactions for IM at time t ,
- $Z_i^{(X)}(t)$ — = 0, zero-net funding transactions for VM or collateral at time t ,
- $Z_i^{(K)}(t)$ — = $-\phi_i(t)K_i(t)$, value of funding transactions for capital, where $\phi_i(t) \in [0, 1]$ is the fraction of risk capital allocated to the saving account for funding purpose.

The cash accounts, cont'd

Initially, the balances of the parties' saving accounts are

$$\beta_{m,B}(0) = -V_0 + \phi_B(0)K_B(0), \quad \beta_{m,C}(0) = V_0 + \phi_C(0)K_C(0),$$

and the initial values of the hedging portfolios are

$$\Pi_B(0) = -V_0, \quad \text{and} \quad \Pi_C(0) = V_0.$$

Here, V_0 is the initial premium payment paid by or received by B , depending on its being positive or negative.

The rise of the funding costs

the total value of cash of party B evolves according to

$$\begin{aligned}d\beta_B(t) &= d\beta_{m,B}(t) + dZ_B^{(I)}(t) + dZ_B^{(X)}(t) + dZ_B^{(K)}(t) \\ &= \left((r_t + x_B)\beta_{m,B}(t) - x_B^{(I)}I_B(t) - x_B^{(X)}X_B(t) - \gamma_B^{(K)}K_B(t) \right) dt,\end{aligned}\tag{5}$$

which is subject to initial balance $\beta_B(0) = -V_0$ due to making the premium payment (or taking the payment, if positive).

The saving account

While $I_B(t)$, $X_B(t)$ and $K_B(t)$ are specified exogenously, $\beta_{m,B}(t)$ evolves according to

$$\begin{aligned}d\beta_{m,B}(t) &= \left((r_t + x_B)\beta_{m,B}(t) - x_B^{(I)} I_B(t) - x_B^{(X)} X_B(t) - \gamma_B^{(K)} K_B(t) \right) dt \\ &\quad + d[\phi_B K_B] - \partial_S V_e(t) dZ_S(t) + \lambda_C^{(Q)} [V(\tau_C = t) - V_e(t)] dt, \\ \beta_{m,B}(0) &= -V_0 + \phi_B K_B(0),\end{aligned}\tag{6}$$

so that the saving account that takes the P&L from hedge, margin/collateral revisions and capital revisions.

Definition

Funding valuation adjustment (FVA) to party B is the expected value of excess cost due to the funding spreads for various funding transactions:

$$FVA_B = E_0^Q \left[e^{-\int_0^{\tau \wedge T} r_s ds} \beta_B(\tau \wedge T) \right] - \beta_B(0).$$

This definition tolerates the mispricing of derivatives.

Proposition

To party B, the funding valuation adjustment is given by

$$FVA_B = FCA_B + MVA_B + CoIVA_B + KVA_B, \quad (7)$$

Proposition (cont'd)

where

$$\begin{aligned} FCA_B &= E_0^Q \left[\int_0^{T \wedge \tau} x_B e^{-\int_0^t r_s ds} \beta_{m,B}(t) dt \right], \\ MVA_B &= - E_0^Q \left[\int_0^{T \wedge \tau} x_B^{(I)} e^{-\int_0^t r_s ds} I_B(t) dt \right], \\ CoIVA_B &= - E_0^Q \left[\int_0^{T \wedge \tau} x_B^{(X)} e^{-\int_0^t r_s ds} X_B(t) dt \right], \\ KVA_B &= - E_0^Q \left[\int_0^{T \wedge \tau} \gamma_B^{(K)} e^{-\int_0^t r_s ds} K_B(t) dt \right], \end{aligned} \tag{8}$$

and $\beta_{m,B}(t)$ evolving according to (6) \square

- It is the most general results so far.
 - It is valid for incomplete markets.
 - It includes those of Burgard and Kjaer (2012), Green and Kenyon (2015), etc.
 - Can be adapted to OTC (CSA or No-CSA) or CCR trades.
- The MtM value for calculating LGD can only be $\hat{V}_e(t)$.

“The value to me”

- The value to a trader is the value with which the risk-neutral return is the risk-free rate.
- Let $V_0^{(i)}$ be the value to party i , then (Li and Wu, 2015)

$$\begin{aligned}V_0^{(B)} &= V_f(0) + FVA_B(-V_0^{(B)}), \\ -V_0^{(C)} &= -V_f(0) + FVA_C(V_0^{(C)}),\end{aligned}\tag{9}$$

which are nonlinear in general.

- In general,

$$V_0^{(B)} \neq V_0^{(C)}!$$

Table of Contents

- 1 xVA — the new paradigm of derivatives pricing
- 2 Risk-neutral valuation and the bilateral replication strategy
- 3 The rise of other xVA
- 4 Market funding liquidity risk premium and asset-liability symmetry

Proposition

Assume independence between market funding risk and counterparty default risks. When all but the systematic (or market) funding risk premium, x_m , are ignored, the bid and ask prices of a derivative are identical and are given by

$$V_0^{(B)} = \frac{V_f(0)}{1 + x_m E_0^Q [\tau \wedge T]} = V_0^{(C)} \quad \square$$

- In risk management
 - Deduct FVA from CET1 capital (Albabese *et al.*, 2015); or
 - We propose the *VaR* or *CVaR* measure for funding risks, under the \mathbb{P} measure.
 - Stress testing funding risks.
 - Set the duration equal to the reporting period.
- In accounting
 - We should consider using the *realized funding costs*,

$$FC_B(t) = \int_0^t g_B(u) du, \quad (10)$$

for P&L attribution.

The xVA




Figure 1. The xVA for the 20-year ATM swap.

Thank You!

www.math.ust.hk/~malwu